Navigation Links
Predicting the age at menopause of women having suffered from childhood cancers
Date:12/4/2012

This press release is available in French.

This study provided important data about the fertility window of women who had suffered from childhood cancer and information concerning the associated risk factors, but did not confirm the greater risk of premature menopause (before the age of 40) that was reported by the American studies.

The results were published in the review Human Reproduction of November 15.

Women who have suffered from childhood cancer are known to run a greater risk of premature menopause. However, data about the associated risk factors is limited. Researchers from unit 1018 "Centre for Research in Epidemiology and Population Health (CESP)" (Inserm/Universit Paris-Sud/Institut Gustave Roussy) and from the AP-HP analyzed the data from a French cohort, named Euro2k, concerning 1522 survivors of childhood cancer diagnosed between 1945 and 1986 when they were under 18, initially in order to study the mortality rate. The study estimated the radiation doses received at the ovaries by the women in this cohort who had been treated by radiotherapy. 706 of these women filled in a detailed questionnaire about their state of health. 32% of these women had already reached the age of 40 years; 7% were over 50 years of age. The research team studied the age at menopause of these women and the potentially associated risk factors. The researchers based this study on self-reported questionnaires sent to the women in order to obtain information about the menopause, without confirming by measuring FSH levels.

Analysis of this data showed that 97 women (13,7%) were menopaused at a median age of 44 years, in other words, 7 years earlier than the general population. For a third of these women (36%), menopause was surgically induced.

The researchers concentrated on the risk factors of menopause in these women, who had been subjected to various cancer treatments during childhood. It appeared that being treated during puberty was associated with a risk of non-surgical menopause. At a given age, the maximum risk of early menopause was observed in women who had been treated after the onset of puberty with alkylating agents (either alone or along with even a minimum dose of radiation to the ovaries, for example 0.01 Gray). Menopause occurred on average 4 years earlier in women who had been exposed to these agents. Having undergone unilateral oophorectomy is also associated with a 7-year earlier age at menopause.

The results showed that women who had suffered from a childhood cancer were more likely to suffer from early menopause, but did not conform the high risk of premature menopause (in other words, before 40 years of age), such as was reported in the American studies. This is probably due to the difference between the populations studied (there were no cases of leukemia or lymphoma in the Euro2k cohort population).

"In this cohort , very few women had received high doses of radiotherapy in order to receive bone marrow transplants, and only 21% of them (i.e. twice the occurrence of the general population) suffered premature menopause before the age of 40″, explained Ccile Teinturier, the principal writer of the study. The main risk factors associated to these cases of premature menopause are: the older the women is when being treated for cancer, the dose of alkyating agents such as Cyclophosphamide or Melphalan received during bone marrow transplants, and the radiation dose received at the ovaries.

"This study provided information about the risk factors affecting the fertility window of women who have suffered from childhood cancer. This new data should help both to inform patients who are at risk of premature menopause, by advising them not to delay their first pregnancy until after the age of thirty, and to reassure women who present a low risk" concluded Ccile Teinturier.

It is planned to extend Cohort Euro2k to cover all patients treated for solid cancers who were under 18 years of age before the year 2000 inFrance. The aim is to study the impact of high-dose chemotherapy on the occurrence of premature menopause.


'/>"/>
Contact: Inserm press office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related biology news :

1. Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada
2. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
3. Discovery of mechanisms predicting response to new treatments in colon cancer
4. Predicting how patients respond to therapy
5. New model could help fill data gap in predicting historical air pollution exposure
6. Cellular landscaping: Predicting how, and how fast, cells will change
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Menopause evolved to prevent competition between in-laws
9. Is long-term weight loss possible after menopause?
10. Early menopause: A genetic mouse model of human primary ovarian insufficiency
11. Long menopause allows killer whales to care for adult sons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology: